Renally Excretable Molybdenum Disulfide Nanoparticles as Contrast Agents for Dual-Energy Mammography and Computed Tomography
Bioconjugate Chemistry · 2024
DOI: 10.1021/acs.bioconjchem.4c00508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2024. Verfasst von Lenitza M Nieves und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States. Hauptthemen laut MEDLINE: Molybdenum, Disulfides, Contrast Media, Tomography, X-Ray Computed. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Compared with conventional mammography, contrast-enhanced dual-energy mammography (DEM) can improve tumor detection for people with dense breasts. However, currently available iodine-based contrast agents have several drawbacks such as their contraindication for use with renal insufficiency, high-dose requirement, and suboptimal contrast production. Molybdenum disulfide nanoparticles (MoS2 NPs) have been shown to attenuate X-rays due to molybdenum's relatively high atomic number while having good biocompatibility. However, work exploring their use as X-ray contrast agents has been limited. In this study, we have developed a novel aqueous synthesis yielding ultrasmall, 2 nm MoS2 NPs with various small molecule coatings, including glutathione (GSH), penicillamine, and 2-mercaptopropionic acid (2MPA). These nanoparticles were shown to have low in vitro cytotoxicity when tested with various cell lines at concentrations up to 1 mg/mL. For the first time, these particles were shown to generate clinically relevant contrast in DEM. In DEM, MoS2 NPs generated higher contrast than iopamidol, a commercially available X-ray contrast agent, while also generating substantial contrast in CT. Moreover, MoS2 NPs demonstrated rapid elimination in vivo, mitigating long-term toxicity concerns. Together, the results presented here suggest the potential utility of MoS2 NPs as a dual-modality X-ray contrast agent for DEM and CT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
- Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
- Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
- Department of Pharmaceutical Sciences, St. Joseph's University, Philadelphia, Pennsylvania 19131-1308, United States.
- Department of Physics, St. Joseph's University, Philadelphia, Pennsylvania 19131-1308, United States.
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
ORCID-Profile: Emily K Berkow, Katherine J Mossburg, David P Cormode
Förderung
- NIBIB NIH HHS
- NCI NIH HHS
- National Cancer Institute
- National Institute of Biomedical Imaging and Bioengineering
Zitieren
APA
Nieves, L. M., Berkow, E. K., Mossburg, K. J., O, N. H., Lau, K. C., Rosario, D. N., Singh, P., Zhong, X., Maidment, A. D. A., & Cormode, D. P. (2024). Renally Excretable Molybdenum Disulfide Nanoparticles as Contrast Agents for Dual-Energy Mammography and Computed Tomography. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.4c00508
Vancouver
Nieves LM, Berkow EK, Mossburg KJ, O NH, Lau KC, Rosario DN, et al. Renally Excretable Molybdenum Disulfide Nanoparticles as Contrast Agents for Dual-Energy Mammography and Computed Tomography. Bioconjugate Chemistry. 2024. doi:10.1021/acs.bioconjchem.4c00508
BibTeX
@article{Nieves2024,
author = {Nieves, Lenitza M and Berkow, Emily K and Mossburg, Katherine J and O, Nathaniel H and Lau, Kristen C and Rosario, Derick N and Singh, Priyash and Zhong, Xingjian and Maidment, Andrew D A and Cormode, David P},
title = {Renally Excretable Molybdenum Disulfide Nanoparticles as Contrast Agents for Dual-Energy Mammography and Computed Tomography},
journal = {Bioconjugate Chemistry},
year = {2024},
doi = {10.1021/acs.bioconjchem.4c00508}
}
EUVIMED